Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

  • Home
  • 2019
  • August
  • 1
  • Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

Original Source

On August 1, 2019

Post navigation

Previous PostBristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
Next PostNorwegian Cruise Line Partners with Guy Harvey Ocean Foundation to Host Third Annual Conservation Cruise

Related Post

August 16, 2022
  • Business News

More than 1,800 customers in Texas assisted through Entergy’s The Power to Care program

August 16, 2022
  • Business News

Modification to Methodology of the S&P/CLX INTER

August 16, 2022
  • Business News

HII CEO Tours Company Operations in Hawaii and Meets with Military and Civilian Leaders

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219